

USSN 08/870,762
Atty Docket No. 18528.231/226/104

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously presented) A method of treating obesity in a human subject comprising administering to said subject an effective amount of a composition comprising an anti-obesity agent consisting of an amylin or an amylin agonist and a pharmaceutically acceptable carrier.
2. (Original) A method according to claim 1 wherein said amylin agonist is an amylin agonist analogue.
3. (Previously presented) A method according to claim 2 wherein said amylin agonist analogue is ^{25,28,29}Pro-h-amylin [SEQ ID NO:1].
4. (Original) A method according to claim 1 wherein said amylin or amylin agonist is administered subcutaneously.
5. (Original) A method according to claim 4 wherein said amylin or amylin agonist is administered from 1 to 4 times per day.
6. (Original) A method according to claim 5 wherein said amylin or amylin agonist is administered in an amount from 30 µg/dose to 300 µg/dose.
7. (Previously presented) A method of treating obesity in a human subject comprising administering to said subject an amount of a composition comprising an amylin or an

BEST AVAILABLE COPY

Amylin 858-552-2212

Dec 06, 2005 09:54AM PST >USPTO

Pg 4 of 6

USSN 08/870,762

Atty Docket No. 18528.231/226/104

amylin agonist effective to treat obesity, with the proviso that the composition does not contain a cholecystokinin or a cholecystokinin agonist.

8. (Previously presented) The method of claim 1, 2 or 3 wherein said treatment of obesity of said subject comprises administration of said effective amount of an anti-obesity agent consisting of an amylin or an amylin agonist for at least about four weeks.

9. (Previously presented) A method according to claim 1, 2 or 3 wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin agonist is administered QID in an amount of 30 μ g/dose.

10. (Previously presented) A method according to claim 1, 2 or 3 wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin agonist is administered TID or QID in an amount of 60 μ g/dose.

11. (Previously presented) A method according to claim 1, wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or an amylin agonist is administered in an amount of about 0.01 milligrams per day to about 5 milligrams per day.

12. (Previously presented) A method according to claim 1, wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin agonist is administered in an amount of about 0.05 milligrams per day to about 2 milligrams per day.

13. (Previously presented) A method according to claim 1, wherein the composition comprising an effective amount of an anti-obesity agent consisting of an amylin or amylin

USSN 08/870,762
Atty Docket No. 18528.231/226/104

agonist is administered in an amount of about 0.1 milligrams per day to about 1 milligram per day.

14. (Previously presented) A method of treating obesity in a human subject comprising administering to said subject a composition comprising a compound selected from the group consisting of amylin, amylin agonists, and pharmaceutically acceptable salts thereof.

15. (Previously presented) The method of claim 1, 2 or 3, wherein the weight of said human subject is lower following four weeks of treatment.

16. (Previously presented) A method of treating obesity in a human subject comprising administering to said subject an effective amount of a composition consisting essentially of an amylin or an amylin agonist.